Effect of Chatushashti Prahari Pippali in the management of Post COVID syndrome

Prospective double arm placebo controlled clinical study to evaluate the efficacy of â??Chatushashti Prahari Pippaliâ?? in the management of Post COVID syndrome as Rasayana therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/031667

Enrollment

Registered

2021-03-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B998- Other infectious disease

Interventions

Intervention1: Chatushashti Prahari Pippali along with Rehabilitation program by WHO: In group A patients will be treated with capsules of Chatushashti Prahari Pippali 500 mg BD along with Rehabilitat

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients willing to comply with all study procedures and availability for the duration of the study 2. Documented prior COVID-19 infection as evidenced by: a. Detection of SARS-CoV-2 RNA or antigen in nasopharyngeal swab, sputum, or other sample source or b. A positive antibody test using an assay that has received emergency use authorization and a history of clinical manifestation compatible with COVID-19. 3. Patients having two negative tests after previous COVID infection but having lingering symptoms of the disease

Exclusion criteria

Exclusion criteria: 1. Positive SARS-CoV-2 PCR at the screening visit 2. Patients having severe symptoms of Post COVID 19 syndrome with co-morbidities requiring hospitalization 3. History of any of the following in the past 14 days: fever > 38.2 degrees Celsius; new or worsening respiratory symptoms (e.g. cough, dyspnea) 4. Patients having uncontrolled cardiac, renal, hepatic disease, malignancy, AIDS 5. Pregnant and lactating women 6. Patients taking phenytoin, propranolol, theophylline (as Pippali has moderate interaction with the absorption of these drugs) 7. Patients having or progressive towards serious sequelaesuch as thromboembolic complications 8. COVID-19 patients whose acute illness required intensive care 9. SpO2

Design outcomes

Primary

Measure	Time frame
Improvement in the symptoms of Post COVID syndromeTimepoint: 8 weeks	—

Secondary

Measure	Time frame
Improvement in the quality of life of the patientTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Mandip Goyal

Institute of Teaching and Research in Ayurveda, Jamnagar

mandipgoyal22@gmail.com9427572306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026